Radiolabeled antibody tumor dosimetry
Read Online

Radiolabeled antibody tumor dosimetry

  • 747 Want to read
  • ·
  • 21 Currently reading

Published by Published for the American Association of Physicists in Medicine by the American Institute of Physics in New York, NY .
Written in English


  • Cancer -- Radioimmunotherapy.,
  • Radiation -- Dosimetry.,
  • Monoclonal antibodies -- Therapeutic use.

Book details:

Edition Notes

Includes bibliographical references.

Statementreport of Task Group No. 2, AAPM Nuclear Medicine Committee.
SeriesAAPM report,, no. 40, Medical physics ;, 20 (2), pt. 2, Mar/Apr 1993, Medical physics monograph ;, no. 20 (2), pt. 2
ContributionsAmerican Association of Physicists in Medicine. Nuclear Medicine Committee.
LC ClassificationsRC271.M65 R33 1993
The Physical Object
Paginationp. 499-610 :
Number of Pages610
ID Numbers
Open LibraryOL1034679M
ISBN 101563962330
LC Control Number93229184

Download Radiolabeled antibody tumor dosimetry


Introduction: Radiolabeled antibody tumor dosimetry. Donald J. Buchsbaum. Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, Alabama ‐ Search for more Cited by: 5. Title: Introduction: Radiolabeled antibody tumor dosimetry Created Date: 7/12/ PM. Radiolabeled antibody tumor dosimetry. Wessels B.W., Buchsbaum D.J. () Dosimetry of Radiolabeled Antibodies. In: Smith A.R. (eds) Radiation Therapy Physics. Medical Radiology (Diagnostic Imaging and Radiation Oncology). .

Introduction: Radiolabeled antibody tumor dosimetry Donald J. Buchsbauma) Department of Radiation Oncology, University Alabama at Birmingham, Birmingham, Alabama Barry W. Wessels. RADIOLABELED ANTIBODY TUMOR DOSIMETRY. Carrasquillo J. () Imaging and dosimetry determinations using radiolabeled antibodies. In: Rosen S.T., Kuzel T.M. (eds) Immunoconjugate Therapy of Hematologic Malignancies. Cancer . It is necessary to determine the quantity of radiolabeled antibody to administer to maximize the radiation dose to the tumor while not exceeding tolerance levels of critical normal tissues, In contrast to external beam radiation therapy dosimetry, the tumor dosimetry for radiolabeled antibody therapy is dependent on a number of variables including: (1) kinetics of biodistribution, tumor uptake and retention of the radiolabeled antibody.

  Abstract. We reviewed In-DOTA-anti-CD45 antibody (BC8) imaging and bone marrow biopsy measurements to ascertain the biodistribution and biokinetics of the radiolabeled antibody .   Biodistribution studies based on organ harvesting represent the gold standard pre-clinical technique for dose extrapolations. However, sequential imaging is becoming increasingly popular as it allows the extraction of longitudinal data from single animals, and a direct correlation with deterministic radiation effects. We assessed the feasibility of mouse-specific, microPET-based dosimetry . The profound differences in therapy did not seem to be dependent on levels of I-mAb tumor-binding or antibody-dependent cytotoxicity. Instead, the microscopic intratumoral dosimetry seemed to be critical with the I-anti-MHCII, delivering more concentrated and therefore substantially higher radiation dose to tumor . Cancer Therapy with Radiolabeled Antibodies Providing a multidisciplinary and international context, some of the world’s leading experts examine the problems and prospects of RAIT from radiation, .